Reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Gelvin (1983), professor of history at University of California, Los Angeles Mark Ravina (1983), professor of Japanese history at the University of Texas at Austin Jonathan Zimmerman (1983), professor of History of Education at the University of Pennsylvania Graduate School of Education Gideon Rosen (1984), professor of philosophy at Princeton University Jordan Sand (1984), professor Japanese history at Georgetown University Thomas Sugrue (1984), historian of the 20th century United States Jamsheed Choksy (1985), chair of Eurasian studies at Indiana University Bloomington Noam Elkies (1985), mathematician, youngest full professor at Harvard William Deresiewicz (1985), literary critic Louis Warren (1985), professor of Western U.S. history at the University of California, Davis Alexander Argüelles (1986), polyglot and professor at the American University in the Emirates; son of poet Ivan Argüelles Tobias Hecht (1986), anthropologist, ethnographer, and translator; winner of the 2002 Margaret Mead Award Alva Noë (1986), professor of philosophy at University of California, Berkeley Anthony B. Pinn (1986), professor of religion at Rice University Ritu Birla (1987), historian of modern South Asia, director of University of Toronto's Asian Institute Scott J. Shapiro (1987), professor of law and philosophy at Yale Law School, director of the Yale Center for Law and Philosophy Irene Tucker (1987), literary critic, professor at University of California, Irvine Katherine B. Crawford (1988), professor of gender studies and history at Vanderbilt University Leslie M.
== Classification == Wounds can be broadly classified as either acute or chronic based on time from initial injury and progression through normal stages of wound healing. Both wound types can further be categorized by cause of injury, wound severity/depth, and sterility of the wound bed. Several classification systems have been developed to describe wounds and guide their management. Some notable classification systems include the CDC's Surgical Wound Classification, the International Red Cross Wound Classification, the Tscherne classification, the Gustilo-Anderson classification of open fractures, and the AO soft tissue grading system.
==== Indications ==== Nabiximol, sold under the trade name Sativex®, is a natural mixture of tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio. Although not approved in the United States, Nabiximol is approved in some European countries as well as Canada for use as an buccal spray for symptomatic relief of spasticity and neuropathic pain in multiple sclerosis (MS). Different reviews were conducted to examine the effects of nabiximol on spasticity in multiple sclerosis, but their results were inconsistent. As some systemic reviews concluded that nabiximols is efficient in refractory spasticity of multiple sclerosis not responsive to other standard treatment, it may be considered as an adjuvant therapy to the standard therapy.
=== October === 1 October – John Braggins, botanist and bryologist (University of Auckland, Auckland War Memorial Museum) (born 1944). 2 October – Mac Gardner, clinical geneticist (University of Otago, University of Melbourne) (born 1942). 4 October – Gordon Keys, atmospheric scientist (DSIR, NIWA), Royal Society of New Zealand Science and Technology Silver Medal (1995) (born 1930). 6 October – Margaret, Lady Liley, paediatrician, general practitioner and farmer (born 1928). 7 October – Graham Bell, police officer and television presenter (Police Ten 7) (born 1946). 8 October – Wally Yovich, businessman, local politician and philanthropist, Whangārei District Councillor (1989–1995) (born 1939). 9 October – Cliff Tait, aviator, politician and writer, Hamilton City Councillor (1992–1995) (born 1929). 10 October – Roger Harris, cricketer (Auckland, national team) (born 1933). 11 October – Richard Nottage, diplomat and public servant, ambassador to Indonesia (1980–1982) and Japan (1987–1988), permanent representative to the UN in Geneva (1984–1987), Secretary of Foreign Affairs and Trade (1991–1999) (born 1939). 15 October – Jim Bolger, politician, MP for King Country (1975–1996) and Taranaki-King Country (1996–1998), Minister of Labour (1978–1984), leader of the National Party (1986–1997), Prime Minister (1990–1997), Ambassador to the United States (1998–2002), chancellor of the University of Waikato (2007–2019), Privy Counsellor (since 1991), Member of the Order of New Zealand (since 1997) (born 1935). 20 October – So You Think, Hall of Fame Thoroughbred racehorse, W. S.
== Reversed phase SPE == Reversed phase SPE separates analytes based on their polarity. The stationary phase of a reversed phase SPE cartridge is derivatized with hydrocarbon chains, which retain compounds of mid to low polarity due to the hydrophobic effect. The analyte can be eluted by washing the cartridge with a non-polar solvent, which disrupts the interaction of the analyte and the stationary phase. A stationary phase of silicon with carbon chains is commonly used. Relying on mainly non-polar, hydrophobic interactions, only non-polar or very weakly polar compounds will adsorb to the surface.
Sources: en.wikipedia.org
=== Radiation protection associations === The Association of German Radiation Protection Physicians (VDSÄ) was formed in the late 1950s from a working group of radiation protection physicians of the German Red Cross and was founded in 1964. It was dedicated to the promotion of radiation protection and the representation of medical, dental, and veterinary radiation protection concerns to the public and the health care system. In 2017, it was merged into the Professional Association for Radiation Protection. The Austrian Association for Radiation Protection (ÖVS), founded in 1966, pursues the same goals as the Association for Medical Radiation Protection in Austria. The Professional Association for Radiation Protection for Germany and Switzerland is networked worldwide.
Mass cytometry is a high-dimensional single-cell analysis technique that integrates flow cytometry with time of flight mass spectrometry. It is used for the determination of the properties of cells (cytometry). In this approach, antibodies are conjugated with isotopically pure elements, and these antibodies are used to label cellular proteins. Cells are nebulized and sent through an argon plasma, which ionizes the metal-conjugated antibodies. The metal signals are then analyzed by a time-of-flight mass spectrometer. The approach overcomes limitations of spectral overlap in flow cytometry by utilizing discrete isotopes as a reporter system instead of traditional fluorophores which have broad emission spectra.
== Pharmacokinetics == Pegcetacoplan exhibits proportional exposure with increasing doses and reaches peak concentration within 4.5–6 days after a single subcutaneous dose. Steady-state concentrations are achieved in about 4–6 weeks of treatment, with average serum trough concentrations ranging from 655 to 706 μg/mL. Pegcetacoplan is metabolized into smaller peptides and amino acids and has a median effective elimination half-life of approximately 8.0 days in people with paroxysmal nocturnal hemoglobinuria.
In 1795, observing the toll that poor nutrition took on his men, Napoleon announced a prize of 12,000 francs to anyone who could improve upon the prevailing food preservation methods of the time. In 1810, Nicholas Appert claimed the prize after devising a method of preserving food in which tightly sealing food inside a bottle and maintaining it at high temperature for certain period of time made the food safe for consumption until opening, using glass jars sealed with corks and boiling water. A trial in which food preserved by this method was sent overseas with French troops succeeded. Appert was given the money on condition that he make his discovery public, and duly published The Art of Preserving Animal and Vegetable Substances. The French Navy began using his methods. The Grande Armée experimented with issuing canned foods to its soldiers. However, the slow process of canning and the even slower development and transport stages prevented large amounts from being shipped across the French Empire, and the wars ended before the process was perfected. A major difficulty that presented itself was the use of glass, which was heavy, fragile, and could explode under internal pressure. Appert's work was improved upon by Philippe de Girard in 1811, when he pioneered a method of preserving food in metal cans. It was patented in Britain on his behalf by Peter Durand, who took the credit as its inventor. Girard, a Frenchman, preferred the entrepreneurial environment of Britain, but could not have taken out a patent in a country with which his own country was at war with.
where A is mass number, Z is atomic number, mH is the atomic mass of a hydrogen atom, mn is the mass of a neutron, and c is the speed of light. Thus, the mass of an atom is less than the mass of its constituent protons and neutrons, assuming the average binding energy of its electrons is negligible. The binding energy B is expressed in energy units, using Einstein's mass-energy equivalence relationship. The binding energy also provides an estimate of the total energy released from fission. The curve of binding energy is characterized by a broad maximum near mass number 60 at 8.6 MeV, then gradually decreases to 7.6 MeV at the highest mass numbers. Mass numbers higher than 238 are rare. At the lighter end of the scale, peaks are noted for helium-4, and the multiples such as beryllium-8, carbon-12, oxygen-16, neon-20 and magnesium-24. Binding energy due to the nuclear force approaches a constant value for large A, while the Coulomb acts over a larger distance so that electrical potential energy per proton grows as Z increases. Fission energy is released when a A is larger than approx. 60. Fusion energy is released when lighter nuclei combine. Carl Friedrich von Weizsäcker's semi-empirical mass formula may be used to express the binding energy as the sum of five terms, which are the volume energy, a surface correction, Coulomb energy, a symmetry term, and a pairing term:
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.